Behavioral Phenotypes and Genetic Syndromes

Chapter
Part of the Autism and Child Psychopathology Series book series (ACPS)

Abstract

Over the past few decades genetic advances have resulted in increasing understanding of the etiology of intellectual disability (ID) syndromes while detailed phenotypic descriptions of behavior and mental disorders have become possible with validated and reliable assessment tools. Although the concept that certain ID syndromes are associated with a recognizable physical, behavioral, and cognitive “phenotype” is not new, it has gained considerable popularity among psychiatrists and psychologists working with this population. In this chapter, we will review the key aspects of behavioral phenotypes and genetic testing before describing some of the phenotypes associated with specific syndromes. For terms in italics, see “Glossary.”

Notes

Glossary

Allele: 

Alternative version of a specific gene responsible for variations in characteristics such as blood type.

Copy number variations (CNVs): 

Abnormal number of copies of sections of the DNA on certain chromosomes. It is usually caused by submicroscopic structural rearrangements such as deletions, duplications, or translocations.

Comparative genomic hybridization (CGH): 

Method for analysis of CNVs in a part of DNA based on microarray technology.

Dominant: 

Alleles that determine the phenotype seen in a heterozygote.

DNA methylation: 

Addition of a methyl group to DNA that may affect the expression of genes. An epigenetic mechanism.

DNA sequencing: 

Process of determining the order of nucleotides containing four bases [(G) guanine, (A) adenine, (T) thymine, and (C) cytosine] in a segment of DNA.

Epigenetic: 

Any factor which influences the phenotype but is not part of the genotype.

FISH (fluorescence in situ hybridization): 

Technique developed in the early 1980s to detect the presence or absence of specific DNA sequences on chromosomes.

Genetic linkage map: 

A map of positions of known genes on the chromosomes.

Genomic imprinting: 

A natural process where certain genes are expressed or silenced (without alteration of their genetic code) depending on whether they are inherited from the mother or the father. Genetic conditions associated with imprinting defects include Angelman and Prader–Willi syndromes.

Genome-wide association studies: 

Examination of the genome for common variants in different individuals usually focusing on associations between SNPs and major diseases.

Karyotype: 

Photographed chromosomes arranged by size.

Linkage: 

The tendency of genes close together on the same chromosome to be inherited together.

Linkage disequilibrium: 

The presence of certain combinations of alleles of closely linked genes on the same chromosome more often than it would be expected by chance.

Locus heterogeneity: 

This occurs when mutations in genes at different chromosomal loci cause the same phenotype.

Mosaicism: 

Presence of two or more populations of cells with different genotypes in one organism. It results from a mutation during development affecting only a subset of the organism’s cells.

Polymerase chain reaction (PCR): 

Technique for copying strands of DNA in order to increase the available amount for study and analysis.

Recessive: 

A gene that is masked in the presence of a dominant allele.

Sequence analysis (also called “gene sequencing” or “sequencing”): 

Lab technique by which the nucleotide sequence for a specific segment of DNA is determined.

Single-nucleotide polymorphisms (SNPs): 

A variant DNA sequence in which the base of a single nucleotide has been replaced by another (e.g., cytosine replaced by thymine).

Tumor suppressor gene: 

A gene that protects a cell from transforming to a cancerous cell. When this gene is mutated and loses or reduces its function, the cell can progress to cancer, usually in combination with other factors.

Uniparental disomy: 

Inheritance of both copies of a chromosome from one parent.

X-linked trait: 

Trait that is caused by mutation of a gene located on the X chromosome.

X-linked recessive disorder: 

A disorder due to a mutation in a gene on the X chromosome that causes the disease traits to be expressed in all males or females who are homozygous for the gene mutation.

References

  1. Anderson, L. T., & Ernst, M. (1994). Self-injury in Lesch Nyhan disease. Journal of Autism and Developmental Disorders, 24, 67–81.PubMedCrossRefGoogle Scholar
  2. Annaz, D., Karmiloff-Smith, A., Johnson, M. H., & Thomas, M. S. C. (2009). A cross-syndrome study of the development of holistic face recognition in children with autism, Down syndrome, and Williams syndrome. Journal of Experimental Child Psychology, 102(4), 456–486.PubMedCrossRefGoogle Scholar
  3. Antar, L. N., Afroz, R., Dictenberg, J. B., Carroll, R. C., & Bassell, G. J. (2004). Metabotropic glutamate receptor activation regulates fragile X mental retardation protein and Fmr1 mRNA localization differentially in dendrites and at synapses. The Journal of Neuroscience, 24(11), 2648–2655.PubMedCrossRefGoogle Scholar
  4. Baker, K., Raymond, F. L., & Bass, N. (2012). Genetic investigation for adults with intellectual disability: Opportunities and challenges. Current Opinion in Neurology, 25, 150–158.PubMedCrossRefGoogle Scholar
  5. Baker, K. D., & Skuse, D. H. (2005). Adolescents and young adults with 22q11 deletion syndrome: Psychopathology in an at-risk group. The British Journal of Psychiatry, 186, 115–120.PubMedCrossRefGoogle Scholar
  6. Basile, E., Villa, L., Selicorni, A., & Molteni, M. (2007). The behavioural phenotype of Cornelia de Lange syndrome: A study of 56 individuals. Journal of Intellectual Disability Research, 51, 671–681.PubMedCrossRefGoogle Scholar
  7. Battaglia, A., Bianchini, E., & Carey, J. C. (1999). Diagnostic yield of the comprehensive assessment of developmental delay/mental retardation in an institute of child neuropsychiatry. American Journal of Medical Genetics, 82, 60–66.PubMedCrossRefGoogle Scholar
  8. Bear, M. F., Huber, K. M., & Warren, S. T. (2004). The mGluR theory of fragile X mental retardation. Trends in Neuroscience, 27(7), 370–377.CrossRefGoogle Scholar
  9. Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., et al. (2009). A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. Journal of Medical Genetics, 46(4), 266–271.PubMedCrossRefGoogle Scholar
  10. Boer, H., Holland, A., Whittington, J., et al. 2002. Psychotic illness in people with Prader Willi syndrome due to chromosome 15 maternal uniparental disomy. Lancet, 359, 135–136.Google Scholar
  11. Bruining, H., de Sonneville, L., Swaab, H., de Jonge, M., Kas, M., van Engeland, H., et al. (2010). Dissecting the clinical heterogeneity of autism spectrum disorders through defined genotypes. PLoS One, 5(5), e10887.PubMedCrossRefGoogle Scholar
  12. Burnside, R. D., Pasion, R., Mikhail, F. M., Carroll, A. J., Robin, N. H., Youngs, E. L., et al. (2011). Microdeletion/microduplication of proximal 15q11.2 between BP1 and BP2: A susceptibility region for neurological dysfunction including developmental and language delay. Human Genetics, 130, 517–528.PubMedCrossRefGoogle Scholar
  13. Cassidy, S. B., & Driscoll, D. J. (2009). Prader–Willi syndrome. European Journal of Human Genetics, 17, 3–13.PubMedCrossRefGoogle Scholar
  14. Clayton-Smith, J. (2001). Angelman syndrome: Evolution of the phenotype in adolescents and adults. Developmental Medicine and Child Neurology, 43, 476–480.CrossRefGoogle Scholar
  15. Collins, A. L., & Sullivan, P. F. (2013). Genome-wide association studies in psychiatry: What have we learned? The British Journal of Psychiatry, 202, 1–4.PubMedCrossRefGoogle Scholar
  16. Cooper, G. M., Coe, G. P., Girirajan, S., Rosenfeld, J. A., Vu, T. H., Baker, C., et al. (2011). A copy number variation morbidity map of developmental delay. Nature Genetics, 43(9), 838–846.PubMedCrossRefGoogle Scholar
  17. Cornish, K., Turk, J., & Hagerman, R. (2008). The Fragile X continuum: New advances and perspectives. Journal of Intellectual Disability Research, 52(6), 469–482.PubMedCrossRefGoogle Scholar
  18. Davies, D. M., Johnson, S. R., Tattersfield, A. E., Kingswood, J. C., Cox, J. A., McCartney, D. L., et al. (2008). Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. The New England Journal of Medicine, 358(2), 200–203.PubMedCrossRefGoogle Scholar
  19. De Waele, K., Ishkanian, S. L., Bogarin, R., Miranda, C. A., Ghatei, M. A., Bloom, S. T., et al. (2008). Long acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight, behaviour and appetite in subjects with Prader-Willi syndrome. European Journal of Endocrinology, 159, 381–388.PubMedCrossRefGoogle Scholar
  20. DYSCERNE—Angelman Syndrome Guideline Development Group (2010) Management of Angelman syndrome: A clinical guideline. Retrieved from http://www.dyscerne.org/dysc/digitalAssets/0/263_Angelman_Guidelines.pdf
  21. Erickson, C. A., Weng, N., Weiler, I. J., Greenough, W. T., Stigler, K. A., Wink, L. K., et al. (2011). Open-label riluzole in fragile X syndrome. Brain Research, 1380, 264–270.PubMedCrossRefGoogle Scholar
  22. Girirajan, S., Rosenfeld, J. A., Cooper, G. M., Antonacci, F., Siswara, P., Itsara, A., et al. (2010). A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay. Nature Genetics, 42, 203–209.PubMedCrossRefGoogle Scholar
  23. Greer, P. L., Hanayama, R., Bloodgood, B. L., Mardinly, A. R., Lipton, D. M., Flavell, S. W., et al. (2010). The Angelman syndrome protein Ube3A regulates synapse development by ubiquitinating arc. Cell, 140(5), 704–716.PubMedCrossRefGoogle Scholar
  24. Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., et al. (2009). Advances in the treatment of fragile X syndrome. Pediatrics, 123, 378–390.PubMedCrossRefGoogle Scholar
  25. Hanson, E., Nasir, R. H., Fong, A., Lian, A., Hundley, R., Shen, Y., et al. (2010). Cognitive and behavioral characterization of 16p11.2 deletion syndrome. Journal of Developmental and Behavioral Pediatrics, 31(8), 649–657.PubMedCrossRefGoogle Scholar
  26. Harrison, P. J., & Owen, M. J. (2003). Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet, 361, 417–419.PubMedCrossRefGoogle Scholar
  27. Hatton, D. D., Sideris, J., Skinner, M., Mankowski, J., Bailey, D. B., Roberts, J., et al. (2006). Autistic behavior in children with fragile X syndrome: Prevalence, stability, and the impact of FMRP. American Journal of Medical Genetics, 140, 1804–1813.Google Scholar
  28. Holmes, G. L., Stafstrom, C. E., & The Tuberous Sclerosis Study Group. (2007). Tuberous sclerosis complex and epilepsy: Recent developments and future challenges. Epilepsia, 48, 617–630.PubMedCrossRefGoogle Scholar
  29. Horowitz, S., Shifman, N., Rivlin, A., Pisante, A., & Darvasi, A. (2005). A survey of the 22q11 microdeletion in a large cohort of schizophrenia patients. Schizophrenia Research, 73(2), 263–267.PubMedCrossRefGoogle Scholar
  30. Horsler, K., & Oliver, C. (2006). The behavioural phenotype of Angelman syndrome. Journal of Intellectual Disability Research, 50, 33–53.PubMedCrossRefGoogle Scholar
  31. Jacquemont, S., Reymond, A., Zufferey, F., Harewood, L., Walters, R. G., Kutalik, Z., et al. (2011). Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. Nature, 478, 97–102.PubMedCrossRefGoogle Scholar
  32. Jinnah, J. A., Visser, J. E., Harris, J. C., Verdu, A. V., Larovere, L., Ceballos-Picot, I., et al. (2006). Delineation of the motor disorder of Lesch–Nyhan disease. Brain, 129, 1201–1217.PubMedCrossRefGoogle Scholar
  33. Jones, A. C., Shyamsundar, M. M., Thomas, M. W., Maynard, J., Idziaszczyk, S., Tomkins, R., et al. (1999). Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. American Journal of Human Genetics, 64(5), 1305–1315.PubMedCrossRefGoogle Scholar
  34. Karayiorgou, M., Morris, M. A., Morrow, B., Shprintzen, R. J., Goldberg, R., Borrow, J., et al. (1995). Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proceedings of the National Academy of Sciences of the United States of America, 92, 7612–7616.PubMedCrossRefGoogle Scholar
  35. Laan, L. A., & Vein, A. A. (2005). Angelman syndrome: Is there a characteristic EEG? Brain & Development, 27(2), 80–87.CrossRefGoogle Scholar
  36. Lesch, M., & Nyhan, W. L. (1964). A familial disorder of uric acid metabolism and central nervous system function. American Journal of Medicine, 36, 561–570.PubMedCrossRefGoogle Scholar
  37. Mefford, H. C., Batshaw, M. L., & Hoffman, E. P. (2012). Genomics, intellectual disability, and autism. The New England Journal of Medicine, 366(8), 733–743.PubMedCrossRefGoogle Scholar
  38. Meyer-Lindenberg, A., Mervis, C. B., & Berman, K. F. (2006). Neural mechanisms in Williams syndrome: A unique window to genetic influences on cognition and behaviour. Nature Reviews Neuroscience, 7, 380–393.PubMedCrossRefGoogle Scholar
  39. Morris, C. A. (1999 Apr 9). Williams syndrome. [Updated 2006 Apr 21]. In R. A. Pagon, T. D. Bird, C. R. Dolan, et al. (Eds.), GeneReviews™ [Internet]. Seattle, WA: University of Washington, Seattle. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK1249/
  40. Najmabadi, H., Hu, H., Garshasbi, M., Zemojtel, T., Abedini, S. S., Chen, W., et al. (2011). Deep sequencing reveals 50 novel genes for recessive cognitive disorders. Nature, 478(7367), 57–63.PubMedCrossRefGoogle Scholar
  41. Northrup, H., Koenig, M. K., & Au, K. S. (1999). Tuberous sclerosis complex. [Updated 2011 Nov 23]. In R. A. Pagon, T. D. Bird, C. R. Dolan, et al. (Eds.), GeneReviews™ [Internet]. Seattle, WA: University of Washington, Seattle. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK1220/
  42. Nyhan, W. L., O’Neill, J. P., Jinnah, H. A., Harris, J. C. (2010). Lesch-Nyhan syndrome. [Updated 2010 Jun 10]. In R. A. Pagon, T. D. Bird, C. R. Dolan, et al. (Eds.), GeneReviews™. Seattle, WA: University of Washington, Seattle. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK1149/
  43. O’Brien, G., & Bevan, R. (2011). Recent advances in behavioural phenotypes as they affect adults. Advances in Mental Health and Intellectual Disabilities, 5(4), 5–14.Google Scholar
  44. Oliver, C., Arron, K., Sloneem, J., & Hall, S. (2008). Behavioural phenotype of Cornelia de Lange syndrome: Case-control study. The British Journal of Psychiatry, 193(6), 466–470.PubMedCrossRefGoogle Scholar
  45. Oliver, C., Berg, K., Moss, J., Arron, K., & Burbridge, C. (2011). Delineation of behavioral phenotypes in genetic syndromes: Characteristics of autism spectrum disorder, affect and hyperactivity. Journal of Autism and Developmental Disorders, 41(8), 1019–1032.PubMedCrossRefGoogle Scholar
  46. Oliver, C., Sloneem, J., Hall, S., & Arron, K. (2009). Self-injurious behaviour in Cornelia de Lange syndrome: 1. Prevalence and phenomenology. Journal of Intellectual Disability Research, 53(7), 575–589.PubMedCrossRefGoogle Scholar
  47. Ousley, O., Rockers, K., Dell, M. L., Coleman, K., & Cubells, J. F. (2007). A review of neurocognitive and behavioural profiles associated with 22q11 deletion syndrome: Implications for clinical evaluation and treatment. Current Psychiatry Reports, 9, 148–158.PubMedCrossRefGoogle Scholar
  48. Prasher, V. P. (1995). Age-specific prevalence, thyroid dysfunction and depressive symptomatology in adults with Down syndrome and dementia. International Journal of Geriatric Psychiatry, 10, 25–31.CrossRefGoogle Scholar
  49. Rauch, A., Wieczorek, D., Graf, E., Wieland, T., Endele, S., Schwarzmayr, T., et al. (2012). Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: An exome sequencing study. Lancet, 380, 1674–1682.PubMedCrossRefGoogle Scholar
  50. Robey, K. L., Reck, J. F., Giacomini, K. D., Barabas, G., & Eddey, G. E. (2003). Modes and patterns of self-mutilation in persons with Lesch-Nyhan disease. Developmental Medicine and Child Neurology, 45, 167–171.PubMedCrossRefGoogle Scholar
  51. Rosner, B., Hodapp, R., Fidler, D., Sagun, J., & Dykens, E. (2004). Social competence in persons with Prader-Willi, Williams and Down’s syndromes. Journal of Applied Research in Intellectual Disabilities, 17, 209–217.CrossRefGoogle Scholar
  52. Sampat, R., Fu, R., Larovere, L. E., Torres, R. J., Ceballos-Picot, I., Fischbach, M., et al. (2011). Mechanisms for phenotypic variation in Lesch-Nyhan disease and its variants. Human Genetics, 129, 71–78.PubMedCrossRefGoogle Scholar
  53. Saul, R. A., Tarleton, J. C. (1998). FMR1-related disorders. [Updated 2012 Apr 26]. In R. A. Pagon, T. D. Bird, C. R. Dolan, et al. (Eds.), GeneReviews™ [Internet]. Seattle, WA: University of Washington, Seattle. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK1384/
  54. Schupf, N. (2002). Genetic and host factors for dementia in Down’s syndrome. The British Journal of Psychiatry, 180, 405–410.PubMedCrossRefGoogle Scholar
  55. Shinawi, M., Liu, P., Kang, S. H., Shen, J., Belmont, J. W., Scott, D. A., et al. (2010). Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. Journal of Medical Genetics, 47(5), 332–341.PubMedCrossRefGoogle Scholar
  56. St Clair, D. (2013). Structural and copy number variants in the human genome: Implications for psychiatry. The British Journal of Psychiatry, 202, 5–6.PubMedCrossRefGoogle Scholar
  57. Stancliffe, R. J., Lakin, K. C., Larson, S. A., Engler, J., Taub, S., Fortune, J., et al. (2012). Demographic characteristics, health conditions, and residential service use in adults with Down syndrome in 25 U.S. states. Intellectual and Developmental Disabilities, 50(2), 92–108.PubMedCrossRefGoogle Scholar
  58. Van Buggenhout, G., & Fryns, J. P. (2009). Angelman syndrome. European Journal of Human Genetics, 17, 1367–1373.PubMedCrossRefGoogle Scholar
  59. Veltman, M. W. M., Ellen, E., & Bolton, P. F. (2005). Autism spectrum disorders in Prader-Willi and Angelman syndromes: A systematic review. Psychiatric Genetics, 15, 243–254.PubMedCrossRefGoogle Scholar
  60. Vissers, L. E., de Ligt, J., Gilissen, C., Janssen, I., Steehouwer, M., de Vries, P., et al. (2010). A de novo paradigm for mental retardation. Nature Genetics, 42, 1109–1112.PubMedCrossRefGoogle Scholar
  61. Weiss, L. A., Shen, Y., Korn, J. M., Arking, D. E., Miller, D. T., Fossdal, R., et al. (2008). Association between microdeletion and microduplication at 16p11.2 and autism. The New England Journal of Medicine, 358, 667–675.PubMedCrossRefGoogle Scholar
  62. Whittington, J., & Holland, A. (2010). Neurobehavioral phenotype in Prader-Willi syndrome. American Journal of Medical Genetics, 154C(4), 438–447.PubMedCrossRefGoogle Scholar
  63. Whittington, J. E., Holland, A. J., Webb, T., Butler, J., Clarke, D., & Boer, H. (2001). Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. Journal of Medical Genetics, 38, 792–798.PubMedCrossRefGoogle Scholar
  64. Wishart, J. G. (2007). Socio-cognitive understanding: A strength or weakness in Down’s syndrome? Journal of Intellectual Disability Research, 51, 996–1005.PubMedCrossRefGoogle Scholar
  65. Wulffaert, J., Berckelaer-Onnes, I., Kroonenberg, P., Scholte, E., Bhuiyan, Z., & Hennekam, R. (2009). Simultaneous analysis of the behavioural phenotype, physical factors, and parenting stress in people with Cornelia de Lange syndrome. Journal of Intellectual Disability Research, 53, 604–619.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Mental Health Sciences UnitCamden & Islington NHS Foundation Trust, University College LondonLondonUK

Personalised recommendations